Morgan Stanley’s Plus Therapeutics PSTV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q2
Hold
0
-$3 7692
2023
Q1
Hold
0
7690
2022
Q4
Hold
0
7874
2022
Q3
Sell
-316
Closed -$70.5K 7833
2022
Q2
$64K Sell
316
-10
-3% -$2.5K ﹤0.01% 6500
2022
Q1
$123K Buy
326
+316
+3,160% +$120K ﹤0.01% 6188
2021
Q4
$4K Buy
+10
New +$5.76K ﹤0.01% 7694
2021
Q3
Hold
0
8003
2021
Q2
Hold
0
7787
2021
Q1
Hold
0
7542
2020
Q4
Hold
0
7095
2020
Q3
Hold
0
6808
2020
Q2
Hold
0
6697
2020
Q1
Hold
0
6676
2019
Q4
Hold
0
6739
2019
Q3
Hold
0
6726
2019
Q2
Hold
0
6718
2019
Q1
Hold
0
6528
2018
Q4
Hold
0
6700
2018
Q3
Hold
0
6777
2018
Q2
Hold
0
6726
2018
Q1
Hold
0
6552
2017
Q4
Hold
0
6500
2017
Q3
Hold
0
6461
2017
Q2
Hold
0
6461
2017
Q1
Hold
0
6386
2016
Q4
Hold
0
6307
2016
Q3
Hold
0
6439
2016
Q2
Hold
0
6368
2016
Q1
Hold
0
6481
2015
Q4
Hold
0
6511
2015
Q3
Hold
0
6419
2015
Q2
Hold
0
5745
2015
Q1
Hold
0
6006
2014
Q4
Hold
0
5767
2014
Q3
Hold
0
6080
2014
Q2
Hold
0
4934
2014
Q1
Hold
0
4720
2013
Q4
Hold
0
4607
2013
Q3
Hold
0
4550
2013
Q2
Hold
0
4497

Other funds holding PSTV

Morgan Stanley's PSTV Position: Q2 2023 in Review

Morgan Stanley held its Plus Therapeutics (PSTV) position steady in Q2 2023 at 0 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #7692.

Morgan Stanley first reported a position in PSTV in Q4 2021 and has held it in 3 quarters since. The position peaked at $123K in Q1 2022. 6 funds tracked by Wall St. Rank hold PSTV as of Q2 2023.

  • Morgan Stanley held 0 shares of Plus Therapeutics worth $0 as of Q2 2023.
  • Morgan Stanley left its Plus Therapeutics share count unchanged in Q2 2023.
  • Plus Therapeutics made up ﹤0.01% of Morgan Stanley's portfolio in Q2 2023, its #7692 holding.
  • Morgan Stanley first reported a position in Plus Therapeutics in Q4 2021 and has held it in 3 quarters since.
  • Morgan Stanley's Plus Therapeutics position peaked at $123K in Q1 2022.
  • 6 funds tracked by Wall St. Rank held Plus Therapeutics as of Q2 2023.

Based on Morgan Stanley's 13F filing for Q2 2023, filed 14 Aug 2023.